Compare CSR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSR | CSTL |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2019 |
| Metric | CSR | CSTL |
|---|---|---|
| Price | $64.43 | $39.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $70.20 | $46.67 |
| AVG Volume (30 Days) | 137.1K | ★ 381.5K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | $273,450,000.00 | ★ $343,530,000.00 |
| Revenue This Year | $7.24 | $2.55 |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $35.23 | ★ N/A |
| Revenue Growth | 5.72 | ★ 10.15 |
| 52 Week Low | $52.76 | $14.59 |
| 52 Week High | $69.15 | $44.28 |
| Indicator | CSR | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 48.34 |
| Support Level | $63.41 | $39.74 |
| Resistance Level | $66.25 | $44.28 |
| Average True Range (ATR) | 1.37 | 1.73 |
| MACD | -0.15 | -0.28 |
| Stochastic Oscillator | 21.71 | 25.33 |
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.